Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Methisoprinol (Isoprinosine), a purine derivative, has been shown to exert a number of immunopharmacological effects, both in vitro and in vivo, in animal and human studies. The agent, somehow mimicking the effects of thymic factors, induces the appearance of phenotypic markers of differentiation on immature precursor T cells; enhances the proliferative response of murine and human lymphocytes to mitogens or antigens, augments helper or suppressor T cell functions and increases the production of lymphotoxin a lymphokine. It has also been shown that this drug can potentiate the effects of macrophage activating factor to stimulate macrophage, and of interferon to protect mice against experimental viral and tumor challenges. In humans, beneficial results have been reported from clinical trials testing the effects of methisoprinol in a variety of diseases including subacute sclerosing panencephalitis (SSPE), acute viral encephalitis, recurrent mucocutaneous infections due to type I and II Herpes viruses as well as in immune restoration of cancer patients with immunodepression following radiotherapy. The drug is also being studied in immunopathological disorders such as rheumatoid arthritis, systemic lupus erythematosus. Sjogren's disease and type A hepatitis. The large spectrum of effects of methisoprinol on a number of immune parameters, the increasing evidence of its therapeutic value in several pathological conditions and its safety of use qualifies this drug as an interesting immunoregulating agent.
 ...
PMID:A recent overview on in vitro and in vivo immunological activities of methisoprinol. 617 7

A placebo controlled clinical trial. Thirty two patients with chronic C hepatitis have been enrolled in a double blinded study to assess the therapeutic effect on an orally given antiviral-immunomodulatory drug, Isoprinosine. Seventeen patients were given Isoprinosine (3 g/day) and fifteen were on placebo. The treatment has been lasted for four months, when patients examined monthly. Clinical signs, liver function tests and side effects were evaluated. At the end of the trial, side effects and elevated serum alanine aminotransferase (ALT/GPT) levels occurred with higher frequency in Isoprinosine-treated patients. The results show that this antiviral drug has no beneficial effect in chronic C hepatitis.
 ...
PMID:[Isoprinosine therapy in chronic hepatitis C (multicenter placebo-controlled double-blind prospective study)]. 768 18

60 children with chronic virus hepatitis B were followed from there to nine years. 34 children received isoprinosine, 6 prednisone and 20 children were without any therapy. There were no cases of death. In 2 cases treated with isoprinosine cirrhosis was found. Eight children with chronic active hepatitis (4 treated with isoprinosine, 1 with prednisone, and 3 without any treatment) had histological recovery. Isoprinosine significantly accelerated seroconversion in HBe system in children with chronic active hepatitis but not in children with persistent, hepatitis. Isoprinosine shortened also the time of normalisation of aminotransferases activity children. Prednisone had no influence on the course of chronic active hepatitis B in treated group.
 ...
PMID:[Course of chronic virus hepatitis B in children and attempts at modifying its treatment]. 769 62